BridgeBio Pharma EPS - Earnings per Share 2018-2026 | BBIO
BridgeBio Pharma annual and quarterly earnings per share history from 2018 to 2026. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- BridgeBio Pharma EPS for the quarter ending June 30, 2026 was $-0.78, a 17.89% decline year-over-year.
- BridgeBio Pharma EPS for the twelve months ending June 30, 2026 was $-3.57, a 13.35% decline year-over-year.
- BridgeBio Pharma 2025 annual EPS was $-3.78, a 31.25% increase from 2024.
- BridgeBio Pharma 2024 annual EPS was $-2.88, a 27.09% decline from 2023.
- BridgeBio Pharma 2023 annual EPS was $-3.95, a 21.17% increase from 2022.
| BridgeBio Pharma Annual EPS | |
|---|---|
| 2025 | $-3.78 |
| 2024 | $-2.88 |
| 2023 | $-3.95 |
| 2022 | $-3.26 |
| 2021 | $-3.90 |
| 2020 | $-3.80 |
| 2019 | $-2.48 |
| 2018 | $-2.12 |
| 2017 | $-1.00 |
| BridgeBio Pharma Quarterly EPS | |
|---|---|
| 2026-06-30 | $-0.78 |
| 2026-03-31 | $-0.84 |
| 2025-12-31 | $-1.00 |
| 2025-09-30 | $-0.95 |
| 2025-06-30 | $-0.95 |
| 2025-03-31 | $-0.88 |
| 2024-12-31 | $-1.43 |
| 2024-09-30 | $-0.86 |
| 2024-06-30 | $-0.39 |
| 2024-03-31 | $-0.20 |
| 2023-12-31 | $-0.97 |
| 2023-09-30 | $-1.08 |
| 2023-06-30 | $-0.98 |
| 2023-03-31 | $-0.92 |
| 2022-12-31 | $-0.91 |
| 2022-09-30 | $-0.93 |
| 2022-06-30 | $-0.07 |
| 2022-03-31 | $-1.35 |
| 2021-12-31 | $-1.00 |
| 2021-09-30 | $-1.06 |
| 2021-06-30 | $-0.66 |
| 2021-03-31 | $-1.18 |
| 2020-12-31 | $-1.01 |
| 2020-09-30 | $-0.98 |
| 2020-06-30 | $-1.03 |
| 2020-03-31 | $-0.78 |
| 2019-12-31 | $-0.60 |
| 2019-09-30 | $-0.51 |
| 2019-06-30 | $-0.71 |
| 2019-03-31 | $-0.66 |
| 2018-12-31 | $0.00 |
| 2018-09-30 | $-0.52 |
| 2017-12-31 | $0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |